Idanwo ti o sopọ mọ itọsọna · Alabọde Ipele

AI ni Aabo Oògùn ati Idanwo Pharmacovigilance

Review adverse-event reports, signal detection and standardized coding in drug-safety surveillance workflows across products.

Jẹmọ itọsọna awọn ọnaAI Ni Aabo Oògùn Ati Itọju elegbogi
Ibeere 1 ti 8

Kini ibi-afẹde akọkọ ti iṣọra elegbogi?

Awotẹlẹ gbogbo ibeere8 ibeere

Awọn idahun ati awọn alaye han bi o ṣe n mu ibeere naa.

  1. Kini ibi-afẹde akọkọ ti iṣọra elegbogi?
    • Ṣiṣawari, ṣe ayẹwo, ati idilọwọ ipalara lati awọn oogun lẹhin lilo wọn
    • Tita awọn oogun tuntun si awọn dokita
    • Eto awọn soobu owo ti oogun
    • Iṣakojọpọ egbogi apẹrẹ
  2. Ninu eto NLP ile-iwosan n2c2 ti a tẹjade, alaye wo ni eto naa jade lati awọn akọsilẹ alaye?
    • Only patients’ handwritten signatures
    • Medication and adverse-event concepts and their relations
    • Only final regulatory decisions
    • Only medicine prices
  3. Kí ni ìtúpalẹ̀ àìbáradé ṣe rí nínú àwọn ibi data data ìṣẹ̀lẹ̀ búburú?
    • Iyatọ idiyele laarin ami iyasọtọ ati awọn oogun jeneriki
    • Ile-iwosan wo ni o fi awọn ijabọ julọ silẹ
    • Awọn orisii oogun-iṣẹlẹ royin diẹ sii nigbagbogbo ju aye iṣiro lọ yoo sọtẹlẹ
    • Awọn ọjọ ipari ti awọn oogun
  4. Kini VigiBase, ni ibamu si Ile-iṣẹ Abojuto Uppsala?
    • A database of randomized clinical-trial efficacy results only
    • A list of confirmed causal side effects for every medicine
    • A commercial catalogue of approved drug prices
    • The WHO global database of reported adverse events for medicines and vaccines
  5. Kini MedDRA ti a lo fun ni awọn opo gigun ti elegbogi?
    • A idiwon egbogi fokabulari fun ifaminsi awọn aati ati awọn ipo
    • A brand ti elegbogi apoti
    • Ohun elo ṣiṣe eto fun awọn dokita
    • Iru ti MRI scanner
  6. Which sequence does UMC describe in its signal-management process?
    • Diagnosis, prescription, dispensing, billing and discharge
    • Detection, validation, prioritisation, assessment and communication
    • Data collection, automatic causality decision, recall and litigation
    • Model training, deployment, billing and marketing
  7. How should a high disproportionality score in a spontaneous-report database be interpreted?
    • As a population incidence rate for all patients
    • As a confirmed causal adverse reaction
    • As a statistical signal for further assessment, not proof that the drug caused the event
    • As proof that no other factor contributed
  8. Which four elements satisfy the minimum ICSR criteria in ICH E2D(R1)?
    • A confirmed causal link, a batch number, a prescriber signature, and a laboratory result
    • A product label, a randomized trial, a treatment response, and a safety committee vote
    • A hospital admission, a known dose, a genetic profile, and a published case report
    • An adverse event or other observation, a suspect or interacting product, an identifiable patient, and an identifiable reporter